CA
MDGL icon

Cetera Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cetera Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$281K Buy
+1,051
New +$248K ﹤0.01% 1984

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cetera Advisors's MDGL Position: Q1 2024 in Review

Cetera Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2024: 1,051 shares worth $281K. The stake represents ﹤0.01% of the portfolio and ranks #1984 among its holdings.

268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Cetera Advisors held 1,051 shares of Madrigal Pharmaceuticals worth $281K as of Q1 2024.
  • Madrigal Pharmaceuticals was a new Cetera Advisors position in Q1 2024.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1984 holding.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.